Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
Heal Clinics is a health and wellness service provider offerring the HEALcare keto...
Heal Clinics is a health and wellness service p...
Intrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with B...
Intrexon Corporation (NASDAQ: XON) is Powering ...
Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncolo...
Spectrum Pharmaceuticals is a leading biotechno...
Translate Bio is a leading mRNA therapeutics company developing a new class of pot...
Translate Bio is a leading mRNA therapeutics co...
Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on...
Outlook Therapeutics is a late clinical-stage b...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedica...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-sta...
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...
At BioMarin, we focus on developing first-in-cl...
Join the National Investor Network and get the latest information with your interests in mind.